

***De novo* design of high-affinity antibody variable regions (Fv) against the SARS-CoV-2 spike protein**

Veda Sheersh Boorla[#], Ratul Chowdhury[#], and Costas D. Maranas^{*}

Department of Chemical Engineering, The Pennsylvania State University, University Park, PA 16802

^{*}*Corresponding author* | Email: costas@psu.edu

[#] *Equal contribution*

Abstract

The emergence of SARS-CoV-2 is responsible for the pandemic of respiratory disease known as COVID-19, which emerged in the city of Wuhan, Hubei province, China in late 2019. Both vaccines and targeted therapeutics for treatment of this disease are currently lacking. Viral entry requires binding of the viral spike receptor binding domain (RBD) with the human angiotensin converting enzyme (hACE2). In an earlier paper¹, we report on the specific residue interactions underpinning this event. Here we report on the *de novo* computational design of high affinity antibody variable regions through the recombination of VDJ genes targeting the most solvent-exposed hACE2-binding residues of the SARS-CoV-2 spike protein using the software tool OptMAVEN-2.0². Subsequently, we carry out computational affinity maturation of the designed prototype variable regions through point mutations for improved binding with the target epitope. Immunogenicity was restricted by preferring designs that match sequences from a 9-mer library of “human antibodies” based on H-score (human string content, HSC)³. We generated 106 different designs and report in detail on the top five that trade-off the greatest affinity for the spike RBD epitope (quantified using the Rosetta binding energies) with low H-scores. By grafting the designed Heavy (VH) and Light (VL) chain variable regions onto a human framework (Fc), high-affinity and potentially neutralizing full-length monoclonal antibodies (mAb) can be constructed. Having a potent antibody that can recognize the viral spike protein with high affinity would be enabling for both the design of sensitive SARS-CoV-2 detection devices and for their deployment as therapeutic antibodies.

Main

Over the last few weeks, several studies on using human or humanized antibodies targeted at the SARS-CoV-2 spike protein have been reported^{4,5,6,7}. In addition, multiple efforts by laboratories and companies (Cellex, GeneTex etc.) for the development of antibody-based tests for SARS-CoV-2 detection are ongoing⁸. At the same time, significant progress towards the isolation and design of vaccines (mRNA-1273

vaccine © 2020 Moderna, Inc) and neutralizing antibodies⁹ has been made. A computational study identified the structural basis for multi-epitope vaccines^{10,11} whereas in another study, the glycosylation patterns of the spike SARS-CoV-2 protein were computationally deduced¹². In addition, fully human single domain anti-SARS-CoV-2 antibodies with sub-nanomolar affinities were identified from a phage-displayed single-domain antibody library. Naïve CDRs were grafted to framework regions of an identified human germline IGHV allele using SARS-CoV-2 RBD and S1 protein as antigens¹³. In another study¹⁴, a human antibody 47D11 was identified to have cross neutralizing effect on SARS-CoV-2 by screening a library of SARS-CoV-1 antibodies. In two other studies, potent neutralizing antibodies were isolated from the sera of convalescent COVID-19 patients^{15,16}. To the best of our knowledge, none of these neutralizing antibody sequences are publicly available. In a follow up effort¹⁷, human antibody CR3022 (which is neutralizing against SARS-CoV-1¹⁸) has been shown to bind to SARS-CoV-2 RBD in a cryptic epitope but without a neutralizing effect for SARS-CoV-2 *in vitro*. Desautels et al¹⁹, performed a machine learning based *in silico* mutagenesis of SARS-CoV-1 neutralizing antibodies to bind to SARS-CoV-2 spike protein. Walter et al²⁰ generated a number of synthetic nanobodies by *in vitro* screening large combinatorial libraries for binding to SARS-CoV-2 spike RBD²⁰. However, studies that perform structure guided design of high affinity antibodies against specific epitopes of SARS-CoV-2 spike protein that may interfere with hACE2 binding are still lacking.

Motivated by these shortcomings, here we explore the *de novo* design of antibody variable regions targeting the most solvent-exposed residues of the spike protein that are also part of the residue contact map involved in hACE2 binding, and trade-off binding energy against human sequence content in the variable region. The goal here is to exhaustively explore the sequence space of all possible variable region designs and report a range of diverse solutions that can serve as potentially neutralizing antibodies (nAb). We find that many different combinations of VDJ genes followed by mutation can yield potentially high affinity variable regions (scored using the Rosetta binding energy function) against an epitope of the spike protein RBD. Pareto optimal designs with respect to binding affinity vs. human content were drawn and five affinity matured designs are detailed in the results section.

We first performed solvent accessibility analysis using the STRIDE²¹ program on the 21 hACE2-binding residues of the SARS-CoV-2 spike protein (S-protein) RBD to define our binding epitope. The top seven residues with the highest solvent accessibility scores (i.e., SAS) are (Arg346, Phe347, Ala348, Tyr351, Ala352, Asn354, and Arg355) comprising our binding epitope (see Figure 1). Furthermore, the epitope is accessible for binding to RBD in the open confirmation of the full spike protein (See Supp. Fig. S8).




Figure 1. The SARS-CoV-2 spike protein RBD in complex with Human ACE2 protein (PDB-id: 6LZG) is shown along with the most solvent accessible residues at the binding interface highlighted in purple. A zoomed view of these seven epitope residues is shown in the inset box. The numbering scheme for the S-protein residues is same as in PDB accession id 6LZG (rcsb.org/structure/6LZG or 6VW1⁷ and 6M0J⁶).






We next used the previously developed OptMAVEN-2.0² software to computationally identify the combination of VDJ genes forming the variable region that best binds the desired epitope. OptMAVEN²² has been used before successfully to design five high affinity CDRs against a FLAG tetrapeptide²³, three thermally and conformationally stable antibody variable regions (sharing less than 75% sequence similarity to any naturally occurring antibody sequence) against a dodecapeptide mimic of carbohydrates²⁴ and two thermostable, high affinity variable heavy chain domains (V_HH) against α -synuclein peptide responsible for Parkinson's disease²⁵. All these designs were experimentally constructed and nanomolar affinities for their respective target antigens was demonstrated.

Through a combination of rotations and translations, OptMAVEN-2.0 identified 3,234 unique antigen poses that presented the epitope to the antibody differently. The combinatorial space of different VDJ genes that upon recombination form the variable region of the prototype antibody was informed by the MAPs database

of antibody parts²⁶. MAPs (see Supp. Info. S1 for link to full database) contains 929 modular antibody (i.e., variable-V*, complementarity determining -CDR3, and joining-J*) parts from 1,168 human, humanized, chimeric, and mouse antibody structures (last updated in 2013). MAPs follows the antibody parts residue numbering convention as listed in the International iMmunoGeneTics (IMGT)²⁷ database. IMGT catalogs antibody parts as variable (V), diversity (D) and joining (J) structure libraries. MAPs stores complete CDR3 parts, C-terminus-shortened V parts (i.e. V* parts) and N-terminus-shortened J parts (J* parts). Note that CDR3 includes the entire D gene and also up to the C-terminus of the V gene and up to the N-terminus of the J gene. In the remainder of the manuscript, the list of parts used to design the variable region are referred to as CDR3, V* and J* parts.

For each one of the 3,234 spike poses, OptMAVEN-2.0 identified a variable region combination composed of end-to-end joined V*, CDR3, and J* region parts that minimized the Rosetta binding energy between the variable region and spike epitope formed by the seven residues. As part of OptMAVEN-2.0, the combinatorial optimization problem was posed and solved as a mixed-integer linear programming (MILP) problem using the cplex solver²⁸. The solution of this problem identifies, for each one of the spike poses, the complete design of the variable region using parts denoted as HV*, HCDR3, HJ* for the heavy chain H and L/KV*, L/KCDR3 and L/KJ* for the light chain-L/K. Only 173 antigen-presenting poses out of 3,234 explored, yielded non-clashing antigen-antibody complexes. These 173 poses were ranked on the basis of their Rosetta binding energies with the spike epitope and classified into 27 clusters (using *k-means*²⁹) in a 19-dimensional space defined by quantitative descriptors of sequence similarity, three-dimensional spatial pose, and the angle at which they bind to the target epitope (see details in original paper²). The top five prototype designs with the highest Rosetta binding energies were present in four clusters and spanned a highly diverse set of choices of MAPs parts (see Table 1) with minimal conservation of the same part among the five prototype designs. The number entries in Table 1 correspond to the id of the gene in the MAPs database (which are identical to the ids used in IMGT). Note that design P5 uses a lambda (L) light chain instead of a kappa (K). Figure 1a plots the pairwise sequence similarity scores of the five antibody variable domains that were used in the top five designs. As expected, the top five prototype designs P1, P2, P3, P4, and P5 are the most dissimilar in their respective CDR3 domains in both light L, heavy H and HV* domain (but not LV*). They are the most similar in the choice of parts for the J* domains (see Figure 2a) reflecting the lack of diversity among possible choices for the J* domains in the MAPs database.

Table 1. V*, CDR3, J* gene ids for the top five prototype variable region designs and corresponding Rosetta binding energies^{30,31}. Antigen poses are described with the angle that the vertical axis through the epitope (shown in pink) centroid and the C β carbon of the residue with greatest z-axis coordinate forms.

Prototype design	Modular Antibody Parts number chosen in each design						Antigen pose (rotation of epitope about vertical axis)	Rosetta binding energy (kcal/mol)
	HV*	HCDR3	HJ*	L/KV*	L/KCDR3	L/KJ*		
P1	82	315	5	61(K)	4(K)	3(K)	 0°	-36.77
P2	52	94	1	61(K)	17(K)	3(K)	 0°	-27.57
P3	105	12	5	6(K)	23(K)	4(K)	 300°	-29.20
P4	79	204	1	2(K)	1(K)	4(K)	 240°	-19.78
P5	108	212	1	37 (L)	5 (L)	5 (L)	 360°	-38.62

Inspection of the interaction of design P1 with the spike epitope reveals strong electrostatic contacts between the S-protein residues Tyr351, Asn354, and Arg355 (see Figure 1c) all of which have been deemed important for hACE2 binding¹. The strongest contacts with the three epitope residues are established by five antibody residues spanning both the heavy and light chains (shown in yellow in Figure 2b). Spike Tyr351 interacts with Ser64 in the HV* domain, Asn354 interacts with Glu38 and Tyr114 in HV* and KV* domains respectively, while spike Arg355 interacts with Asn37 and Asp110 of HV* and HCDR3 domains, respectively, in the stable spike-antibody complex (see Figure 2c).




Figure 2. (a) Pairwise sequence similarity percentages between the members of the six parts that were used to construct the top five prototype variable regions with the lowest Rosetta binding energies with the viral spike epitope. **(b)** The amino acid sequence of prototype design P1 with the different domain parts highlighted in different colors. Spike epitope binding residues are highlighted in yellow. **(c)** Structural view of the strongest epitope-prototype variable region interactions for P1. They imply strong electrostatic capture of three epitope residues by five variable region residues spanning both heavy (H) and light (K) chains.

We next applied Rosetta-based *in silico* affinity maturation (see Methods) for each one of the top five prototype designs shown in Table 1 to further enhance the non-covalent binding between the antibody variable domains and the SARS-CoV-2 spike RBD. This computationally mimics the process of somatic hypermutation leading to eventual affinity maturation of antibodies in B cells. This procedure identified a total of 124 unique variable designs by introducing mutations in the five prototypes (see Figure 3a). We retained 106 designs which achieved both an improvement in the Rosetta binding energy over their respective prototype sequences and also further stabilization (i.e., lower overall Rosetta energy) of the spike-antibody complex (see upper right quadrant of Figure 3a). On average, upon affinity maturation, the binding energy was improved by ~14 kcal/mol and the overall energy was improved by ~37 kcal/mol. Supplementary S2 lists first the starting prototype design (i.e., P1, P2, P3, P4 or P5) followed by the 106 affinity matured designs (labeled as P1.D1, P1.D2, etc). On average, there were 4.5 mutations (Supp. info. S3) between computational affinity matured and prototype variable region designs.

We next assessed the departure of the 106 designed variable regions from fully-human antibody sequences using H-Score³. H-score is defined as the sum of the minimum edit distance between all possible 9-mer fragments in the designed variable region from a library of all 9-mer sequences observed in human antibodies²². The value of H-score is scaled to 100 and normalized by the length of the sequence. An antibody sequence with all 9-mers exactly matching 9-mers of human antibodies will have a perfect H-score of 100. Figure 3b illustrates the trade-off between the Rosetta binding energy vs. H-score for these affinity matured variable region designs. For comparison, we calculated the H-score for the human antibodies CR3022³², 80R³³, S230³⁴ and M396³⁵ which are known to be neutralizing against SARS-CoV-1. These antibodies (including only Fv regions) have an average H-score of 62.98 (stdev: 4.9) which are in the same range as our most human designs (e.g., P3.D1 and P3.D3).

We selected five designs that were on the Pareto optimum curve shown in Figure 3b. The Pareto optimum curve is defined as the collection of designs for which no other design exists that can simultaneously improve upon both criteria (i.e., Rosetta binding energy and H-score). Designs P1.D1 and P1.D2 shown in blue (in Fig. 3b) have the lowest Rosetta binding energies whereas P3.D1 and P3.D3 shown in yellow correspond to the ones with the highest H-scores. Design P4.D1 is an intermediate design that balances both binding energy and H-score. The lowest binding energy designs (P1.D1, P1.D2), irrespective of H-score, would be relevant in ELISA-based *in vitro* detection assays whereas the lowest H-score designs




Figure 3. (a) The 106 out of 124 Rosetta-affinity matured designs that improve upon both energy criteria fall in the top right quadrant. **(b)** Plot of the Rosetta binding energy vs. H-score for the 106 retained affinity-matured sequences. The blue line connects the designs on the Pareto optimum curve between these two design objectives. The three best-binding affinity matured designs (emerging from P1) – P1.D1 and P1.D2 are shown in blue whereas the two most human designs (emerging from P3) – P3.D1 and P3.D3 are shown in yellow. An intermediate design P4.D1 (emerging from P4) is shown in red.

(P3.D1, P3.D3) may offer the highest potential as therapeutic antibodies. In addition, we calculated the Rosetta binding energy between the human CR3022¹⁷ (anti-SARS-CoV-1 antibody) and the SARS-CoV-2 spike protein RBD using complex structure (PDB-id:6W41) to be -56.4 kcal/mol which is very close to the Rosetta binding energy of designs P1.D1 and P1.D2. However, P1.D1 and P1.D2 bind a different epitope on the spike RBD than the one that CR3022 targets (see Supp. Fig S7).

Figure 4 shows the sequence alignment of these five selected affinity matured sequences (i.e., P1.D1, P1.D2, P4.D2, P3.D1, and P3.D3). Shown in red boxes are the conserved positions and in red font the positions with different but of similar type residues. A total of 156 out of 226 aligned positions are conserved among all designs. Table 2 lists the most important (strongest) contacts with the spike protein as informed by an *in silico* alanine scanning (Supp. info. S4) on the spike-binding residues of the variable region designs. In essence, the alanine scanning analysis identifies the loss in binding energy that is incurred upon mutating each residue (one at a time) to alanine.




Figure 4. Sequence alignment of Heavy chain sequences (panel A) and light chain sequences (panel B) of the five pareto optimal affinity matured sequences. Conserved positions are outlined in blue boxes. Positions with same residues across designs are highlighted in red and positions with different amino acid but similar residue type are highlighted in white with red text.

Table 2. List of important contacts between the spike protein epitope residues and residues of each of the selected affinity matured designs. For each contact, the loss in binding energy upon mutation of antibody residue from the interface to alanine is tabulated. The corresponding interacting spike residue is also shown.

Matured antibody Design id	Interface residue from antibody	Interacting spike residue(s)	Loss in binding energy upon mutation to alanine (kcal/mol)	Corresponding variable region
P1.D1	G62	A352	9.69	HV*
	G63	Y351	2.13	HV*
	L65	Y489	1.26	HV*
	Y66	S349	0.53	HV*
	I56	C488	0.94	HV*
P1.D2	F109	K356	2.77	HCDR3
	T65	Y351	1.42	HV*
	Y66	A348,S349	1.06	HV*
	I56	C488	0.94	HV*
	S57	A352	0.71	HV*
P4.D1	A56	L452	0.573	KV*
	D35	R357	0.08	HV*
	G28	T478,G482	0.01	KV*
	T85	N481	0.00	KV*
	L67	V445	0.00	KV*
P3.D1	W64	A352	2.30	HV*
	N57	N354	0.65	HV*
	F107	T345	0.57	KCDR3
	S29	E340	0.14	HV*
	S108	R346	0.12	KCDR3
P3.D3	N57	N354	0.99	HV*
	F107	T345	0.33	KCDR3
	D38	R346	0.18	KV*
	S29	E340	0.22	HV*
	Q106	R346	0.03	KCDR3

Antibodies that strongly bind to the RBD but do not inhibit hACE2 binding have been shown to be neutralizing for SARS-CoV-2 (47D11¹⁴) and for SARS-CoV-1 (CR3022 in combination with CR3014³²). The mechanisms of neutralization of such antibodies are not completely known¹⁴. It is possible that upon binding, these antibodies perturb the interaction network of the RBD with hACE2 thereby rendering RBD-hACE2 binding less effective. In addition, Daniel et al³⁶ showed that nanobody VHH-72 raised against SARS-CoV-1 had a neutralizing effect despite binding to an epitope that does not overlap with the hACE2 residue binding domain. By fusing VHH-72 with a human IgG1 they demonstrated SARS-CoV-2 neutralizing activity. They hypothesized that binding of the nanobody with the trimeric spike protein may disrupt conformational dynamics and consequently prevent binding to hACE2.

In comparison, our design P1.D1 forms strong contacts (see Table 2) with many residues of the RBD which in turn also indirectly interact with hACE2 (see Figure 5). For example, residues L455 and T470 of the RBD are in contact with both hACE2 contacting RBD residues Y449, F490 and P1.D1 contacting RBD

208 residues Y351, I465. By perturbing the inter-residue interaction network of RBD-hACE2 it is plausible that
209 a neutralizing effect can be achieved.




Figure 5. Space filling plot of the P1.D1-RBD complex superimposed on the hACE2-RBD complex. In blue are shown the RBD residues in contact with hACE2 and in green the RBD residues in contact with the P1.D1 designed antibody. In pink are shown all the RBD residues that are in contact with both hACE2 contacting RBD residues and P1.D1 contacting RBD residues. A few residues that are a part of these inter-residue contacts are labelled.

210
211 We also carried out an all-atom Molecular Dynamics (MD) simulation of the best binding design P1.D1 in
212 complex with the RBD of the SARS-CoV-2 spike protein to assess the stability of the complex. Preliminary
213 results for a 50ns trajectory counted an average of ~4 hydrogen bonds (st. dev: 1.5) present at the antibody-
214 antigen interface (Supp. Info. S5 for further details). This is quite encouraging, as in an earlier study³⁷, MD
215 simulation of the hACE2 receptor in complex with the spike protein RBD reported an average of only 2.7
216 hydrogen bonds at the interface. This implies that this design has the potential to competitively bind the
217 RBD of the SARS-CoV-2 spike protein potentially sequestering it from hACE2. This is also corroborated
218 by the Rosetta binding energy value of around -48.3 kcal/mol¹ calculated for the spike protein RBD with
219 hACE2 (from PDB-id: 6lzg) which is weaker by over 7 kcal/mol compared to designs P1.D1 and P1.D2.
220 Finally, it is important to stress that our designs rely on the accuracy of the Rosetta energy function to

recapitulate experimental affinities and that carrying out experimental binding assays are needed to confirm or refute these findings.

Summary

In summary, the goal of this computational analysis was to assess the range of possible antibody designs that can affect binding with the viral spike protein by interacting with residues involved in hACE2 binding. We reported on *de novo* prototype variable regions targeting the most solvent accessible seven-residue epitope in the spike and their (computationally) affinity matured sequences with the lowest Rosetta binding energies. Designs were rank ordered not only in terms of their Rosetta binding energy but also their humanness score metric H-score. We reported complete amino acid sequences for the 106 affinity matured designs as well as the five prototype sequences and V*, CDR3, and J* parts used. Importantly, we would like to note that high affinities of designed antibodies, as modeled using the Rosetta binding energy function, need not necessarily translate to therapeutic effectiveness. The exact mechanisms underlying the therapeutic action of monoclonal antibodies are quite complex and often only partially understood. Nevertheless, we hope that this analysis and data will contribute an important piece to help inform the discovery of high affinity mAb against SARS-CoV-2.

Methods

Antibody design in OptMAVEN-2.0

The initial antibody variable domain sequences were predicted using *de novo* antibody design software tool, OptMAVEN-2.0². Using an interatomic clash-cutoff of 1.25 Å, 173 antigen poses were sampled, and each of which yielded a successful (not necessarily unique) antibody design targeted at the seven most solvent accessible hACE2-binding residues of SARS-CoV-2 spike RBD.

Prior to identifying antibody sequences complimentary to the epitopes, OptMAVEN-2.0 first minimizes the z-coordinate of the epitopes, with their collective centroid set at origin, to allow the *de novo* designed antibody regions (see Supp. Info. S1 for link to entire MAPs fragment library) to bind from the bottom. Next, an ensemble of starting antigen poses is generated by a combination of discrete rotations (about the z-axis) and translations (in x, y, and z) – each of which are subsequently passed into the antibody design step. We started out with 3234 such antigen poses for the SARS-CoV-2 spike protein with the epitopes occupying the most negative z-axis coordinates.

Affinity maturation design in Rosetta

The affinity maturation protocol consisted of an initial refinement of the complex by RosettaDock³⁸ followed by three iterations of backbone perturbation using RosettaBackrub³⁹, interface design using RosettaDesign⁴⁰ and rotamer repacking of the complex using a Monte Carlo based simulated annealing algorithm^{41,42}. During the Rosetta affinity maturation, only amino acids in the variable region within 5 Å from any epitope residue are allowed to mutate. Each affinity matured designed complex was relaxed using FastRelax (with constraints) 10 times and energy minimized (using *Minimize*). For each of these relaxed poses, the binding energy (dG_{separated}) was calculated using the *InterfaceAnalyzer*³¹ application. The entire protocol was implemented in RosettaScripts⁴³ using the REF2015 energy function³⁰ (see Supp. info. S6 for further details). This computational protocol was executed for 8,000 affinity matured sequence-design cycles. The top five variable region designs which show strong interaction energy scores with the viral spike and low immunogenicity (high H-scores) were further investigated to glean insight on the biophysics of interactions at the residue level.

Author contributions

RC designed and performed the OptMAVEN experiments. VSB designed and performed the affinity maturation experiments, MD simulations and related analyses. VSB, RC and CDM wrote the manuscript.

Acknowledgements

This activity was partially enabled by research conducted within the Center for Bioenergy Innovation of US Department of Energy (DE-SC0018420) and US National Science Foundation (NSF) grant CBET1703274.

All computations were performed using the High-Performance Computing facility at The Institute for Computational and Data Sciences Advanced Cyber Infrastructure (ICDS-ACI) at Pennsylvania State University.

References

1. Chowdhury, R. & Maranas, C. D. Biophysical characterization of the SARS-CoV2 spike protein binding with the ACE2 receptor explains increased COVID-19 pathogenesis. *bioRxiv* 2020.03.30.015891 (2020) doi:10.1101/2020.03.30.015891.
2. Chowdhury, R., Allan, M. F. & Maranas, C. D. OptMAVEN-2.0: De novo Design of Variable Antibody Regions Against Targeted Antigen Epitopes. *Antibodies* **7**, 23 (2018).
3. Lazar, G. A., Desjarlais, J. R., Jacinto, J., Karki, S. & Hammond, P. W. A molecular immunology approach to antibody humanization and functional optimization. *Mol. Immunol.* **44**, 1986–1998 (2007).
4. Yan, R. *et al.* Structural basis for the recognition of the SARS-CoV-2 by full-length human ACE2. *Science* **367**, 1444–1448 (2020).
5. Shang, J. *et al.* Structure of mouse coronavirus spike protein complexed with receptor reveals mechanism for viral entry. *PLoS Pathog.* **16**, e1008392 (2020).
6. Lan, J. *et al.* Crystal structure of the 2019-nCoV spike receptor-binding domain bound with the ACE2 receptor. *bioRxiv* 1–20 (2020) doi:10.1101/2020.02.19.956235.
7. Shang, J. *et al.* Structural basis of receptor recognition by SARS-CoV-2. *Nature* 1–8 (2020) doi:10.1038/s41586-020-2179-y.
8. Petherick, A. Developing antibody tests for SARS-CoV-2. *Lancet* **395**, 1101–1102 (2020).
9. Jiang, S., Hillyer, C. & Du, L. Neutralizing Antibodies against SARS-CoV-2 and Other Human Coronaviruses. *Trends Immunol.* (2020) doi:10.1016/j.it.2020.03.007.
10. Saha, R. & Prasad, B. V. In silico approach for designing of a multi-epitope based vaccine against novel Coronavirus (SARS-COV-2). *bioRxiv* 2020.03.31.017459 (2020) doi:10.1101/2020.03.31.017459.
11. Srivastava, S. *et al.* Structural basis to design multi-epitope vaccines against Novel Coronavirus 19 (COVID19) infection, the ongoing pandemic emergency: an in silico approach. *bioRxiv* 2020.04.01.019299 (2020) doi:10.1101/2020.04.01.019299.
12. Shajahan, A., Supekar, N. T., Gleinich, A. S. & Azadi, P. Deducing the N- and O- glycosylation profile of the spike protein of novel coronavirus SARS-CoV-2. *bioRxiv* 2020.04.01.020966 (2020) doi:10.1101/2020.04.01.020966.
13. Wu, Y. *et al.* Fully human single-domain antibodies against SARS-CoV-2. *bioRxiv* 2020.03.30.015990 (2020) doi:10.1101/2020.03.30.015990.
14. Wang, C. *et al.* A human monoclonal 1 antibody blocking SARS-CoV-2 infection. *bioRxiv* 2020.03.11.987958 (2020) doi:10.1101/2020.03.11.987958.

15. Poh, C. M. *et al.* Potent neutralizing antibodies in the sera of convalescent COVID-19 patients are directed against conserved linear epitopes on the SARS-CoV-2 spike protein. *bioRxiv* 2020.03.30.015461 (2020) doi:10.1101/2020.03.30.015461.
16. Ju, B. *et al.* Potent human neutralizing antibodies elicited by SARS-CoV-2 infection. *bioRxiv* 2020.03.21.990770 (2020) doi:10.1101/2020.03.21.990770.
17. Yuan, M. *et al.* A highly conserved cryptic epitope in the receptor-binding domains of SARS-CoV-2 and SARS-CoV. *Science* (80-.). eabb7269 (2020) doi:10.1126/science.abb7269.
18. ter Meulen, J. *et al.* Human Monoclonal Antibody Combination against SARS Coronavirus: Synergy and Coverage of Escape Mutants. *PLoS Med.* **3**, e237 (2006).
19. Desautels, T., Zemla, A., Lau, E., Franco, M. & Faissol, D. Rapid in silico design of antibodies targeting SARS-CoV-2 using machine learning and supercomputing. *bioRxiv* 2020.04.03.024885 (2020) doi:10.1101/2020.04.03.024885.
20. Walter, J. D. *et al.* Synthetic nanobodies targeting the SARS-CoV-2 receptor-binding domain. *bioRxiv* 2020.04.16.045419 (2020) doi:10.1101/2020.04.16.045419.
21. Heinig, M. & Frishman, D. STRIDE: a web server for secondary structure assignment from known atomic coordinates of proteins. *Nucleic Acids Res.* **32**, W500-2 (2004).
22. Li, T., Pantazes, R. J. & Maranas, C. D. OptMAVEN – A New Framework for the de novo Design of Antibody Variable Region Models Targeting Specific Antigen Epitopes. *PLoS One* **9**, e105954 (2014).
23. Entzminger, K. C. *et al.* De novo design of antibody complementarity determining regions binding a FLAG tetra-peptide. *Sci. Rep.* **7**, (2017).
24. Poosarla, V. G. *et al.* Computational de novo design of antibodies binding to a peptide with high affinity. *Biotechnol. Bioeng.* **114**, 1331–1342 (2017).
25. Tiller, K. E. *et al.* Facile affinity maturation of antibody variable domains using natural diversity mutagenesis. *Front. Immunol.* **8**, 986 (2017).
26. Pantazes, R. J. & Maranas, C. D. MAPs: A database of modular antibody parts for predicting tertiary structures and designing affinity matured antibodies. *BMC Bioinformatics* **14**, 168 (2013).
27. Lefranc, M.-P. IMGT, the international ImMunoGeneTics database. *Nucleic Acids Res.* **31**, 307–310 (2003).
28. IBM (2017) IBM ILOG CPLEX 12.7 User's Manual (IBM ILOG CPLEX Division, Incline Village, NV).1.
29. Lloyd, S. P. Least Squares Quantization in PCM. *IEEE Trans. Inf. Theory* **28**, 129–137 (1982).
30. Alford, R. F. *et al.* The Rosetta All-Atom Energy Function for Macromolecular Modeling and Design. *J. Chem. Theory Comput.* **13**, 3031–3048 (2017).

31. Benjamin Stranges, P. & Kuhlman, B. A comparison of successful and failed protein interface designs highlights the challenges of designing buried hydrogen bonds. *Protein Sci.* **22**, 74–82 (2013).
32. Ter Meulen, J. *et al.* Human monoclonal antibody combination against SARS coronavirus: Synergy and coverage of escape mutants. *PLoS Med.* **3**, 1071–1079 (2006).
33. Sui, J. *et al.* Potent neutralization of severe acute respiratory syndrome (SARS) coronavirus by a human mAb to S1 protein that blocks receptor association. *Proc. Natl. Acad. Sci. U. S. A.* **101**, 2536–2541 (2004).
34. Walls, A. C. *et al.* Unexpected Receptor Functional Mimicry Elucidates Activation of Coronavirus Fusion. *Cell* **176**, 1026–1039.e15 (2019).
35. Zhu, Z. *et al.* Potent cross-reactive neutralization of SARS coronavirus isolates by human monoclonal antibodies. *Proc. Natl. Acad. Sci. U. S. A.* **104**, 12123–12128 (2007).
36. Wrapp, D. *et al.* Structural Basis for Potent Neutralization of Betacoronaviruses by Single-domain Camelid Antibodies. *Cell* 2020.03.26.010165 (2020) doi:10.1016/j.cell.2020.04.031.
37. Lupala, C. *et al.* Computational simulations reveal the binding dynamics between human ACE2 and the receptor binding domain of SARS-CoV-2 spike protein. *bioRxiv* 2020.03.24.005561 (2020) doi:10.1101/2020.03.24.005561.
38. Gray, J. J. *et al.* Protein-protein docking with simultaneous optimization of rigid-body displacement and side-chain conformations. *J. Mol. Biol.* **331**, 281–299 (2003).
39. Smith, C. A. & Kortemme, T. Backrub-Like Backbone Simulation Recapitulates Natural Protein Conformational Variability and Improves Mutant Side-Chain Prediction. *J. Mol. Biol.* **380**, 742–756 (2008).
40. Kuhlman, B. *et al.* Design of a Novel Globular Protein Fold with Atomic-Level Accuracy. *Science* (80-.). **302**, 1364–1368 (2003).
41. Leaver-Fay, A., Kuhlman, B. & Snoeyink, J. An adaptive dynamic programming algorithm for the side chain placement problem. *Pac. Symp. Biocomput.* 16–27 (2005).
42. Leaver-Fay, A., Snoeyink, J. & Kuhlman, B. On-the-fly rotamer pair energy evaluation in protein design. in *Lecture Notes in Computer Science (including subseries Lecture Notes in Artificial Intelligence and Lecture Notes in Bioinformatics)* vol. 4983 LNBI 343–354 (Springer, Berlin, Heidelberg, 2008).
43. Fleishman, S. J. *et al.* RosettaScripts: A Scripting Language Interface to the Rosetta Macromolecular Modeling Suite. *PLoS One* **6**, e20161 (2011).